4-(4-O-OCTANOYLCYCLOHEXYLOXY)-CYCLOHEXYL OCTANOATE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MTNLDLPVMUJUHL-UHFFFAOYSA-N
Smiles	CCCCCCCC(=O)OC1CCC(CC1)OC2CCC(CC2)OC(=O)CCCCCCC
InChI	InChI=1S/C28H50O5/c1-3-5-7-9-11-13-27(29)32-25-19-15-23(16-20-25)31-24-17-21-26(22-18-24)33-28(30)14-12-10-8-6-4-2/h23-26H,3-22H2,1-2H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C28H50O5
Molecular Weight	466.69
AlogP	7.95
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	18.0
Polar Surface Area	61.83
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	33.0

Assay Description	Organism	Bioactivity	Reference
Insecticidal activity against second-instar larval stage of Helicoverpa armigera fed with artificial diet containing compound assessed as growth inhibition after 7 days	Helicoverpa armigera	None		Insecticidal activity against second-instar larval stage of Helicoverpa armigera fed with artificial diet containing compound assessed as growth inhibition after 7 days	Helicoverpa armigera	6340.0 ug.mL-1
Insecticidal activity against second-instar larval stage of Spodoptera litura fed with artificial diet containing compound assessed as growth inhibition after 7 days	Spodoptera litura	None		Insecticidal activity against second-instar larval stage of Spodoptera litura fed with artificial diet containing compound assessed as growth inhibition after 7 days	Spodoptera litura	5760.0 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2268568
PubChem	76333994

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).